Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07235228, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
- Trial code
- NCT07235228
- Record updated
- 17 December 2025
- Original description
Multi-center, randomized, double-blind, placebo-controlled, 12 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) on the gut microbiota of IBS patientsRead full original descriptionShow less
Effects of Vivatlac Synbiotic on the Gut Microbiota of Patients With Irritable Bowel Syndrome - A Randomized, Double-blind, Placebo-Controlled, 12 Weeks Clinical Trial
Multi-center, randomized, double-blind, placebo-controlled, 12 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) on the gut microbiota of IBS patients
Inclusion: diagnosed for Irritable Bowel Syndrome using the IBS questionnaire for Health Care Providers of the World Global Gastroenterology Organization; IBS severity assessed with the IBS-Severity Scoring System (IBS-SSS) being ≥ 175 points (indicating medium or severe IBS).
Exclusion: patients currently taking products containing probiotics or have taken this kind of products during the last 3 months; patients currently taking antibiotics or have taken antibiotics during the last 3 months; patients having a concurrent severe illness (malignancies, uncontrolled hypertension or diabetes, hepatic, renal or cardiac dysfunctions, serious neurological disorders, psychosis, respiratory disorders such as asthma or COPD, hyper- or hypothyroidism; patients using motility drugs or dietary fiber supplements withing 2 weeks before study start; patient taking anti-coagulant medication; patients having chronic bowel disorders other than IBS, including inflammatory bowel disease, gastroenteritis, stomach and duodenal cancer, celiac disease; patient being tested positive for presence of Clostridioides difficile; patient being pregnant, lactating, or planning to become pregnant during the next 3 months; patient being diagnosed to have a lactose intolerance; patients have participated in another clinical trial within the last three months.